Breast Cancer Research in New Zealand 2017 Partnership

Associate Professor David Barker
University of Auckland
Funder(s): HRC, Breast Cancer Cure, The New Zealand Breast Cancer Foundation
Development of inhibitors of PC-PLC as anticancer therapeutics
$200,000
24 months

Lay summary

Many patients with metastatic breast cancer do not respond to conventional chemotherapy and better strategies to treat these patients are urgently needed. An enzyme called phosphatidylcholine-specific phospholipase C (PC-PLC) is involved in allowing breast cancer cells to grow and invade other tissues. This project seeks to prepare potent and selective drugs that target PC-PLC in breast cancer. We will prepare and examine the effectiveness of these drugs in reducing cancer cell growth, with the aim of providing new treatment options for patients with triple negative breast cancer.

Back to Funding Recipients